NHS-IL12

Drug Profile

NHS-IL12

Alternative Names: M-9241; MSB0010360; NHS-huIL12; NHS-IL12 human; NHS-IL12/MSB0010360; NHS-muIL12

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Merck Serono
  • Developer EMD Serono; Merck Serono; National Cancer Institute (USA)
  • Class Antineoplastics; Immunotherapies; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Jan 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (SC) (NCT02994953)
  • 14 Dec 2016 EMD Serono and Merck plan the phase Ib COMBO trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (SC) (NCT02994953)
  • 20 Apr 2016 Pharmacodynamics data from a preclinical study in Bladder cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top